Receptor Integral To Or Derived From A Lymphocytic Or Lymphocytic-like Cell (e.g., Nk Cell, Etc.) Patents (Class 424/144.1)
-
Patent number: 8246958Abstract: The invention provides methods of treatment using humanized immunoglobulins that specifically bind to alpha-4 integrin. The methods are useful for treatment of asthma, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, transplant rejection, graft versus host disease, tumor metastasis, nephritis, atopic dermatitis, psoriasis, myocardial ischemia, and acute leukocyte mediated lung injury.Type: GrantFiled: July 17, 2008Date of Patent: August 21, 2012Assignee: Elan Pharmaceuticals, Inc.Inventors: Mary M. Bendig, Olivier J. Leger, Jose Saldanha, Tarran S. Jones, Ted A. Yednock
-
Publication number: 20120207763Abstract: The present application describes organic compounds that are useful for the treatment, prevention and/or amelioration of diseases, particularly pyrrolopyrimidine compounds and derivatives are described which inhibit protein kinases. The organic compounds are useful in treating proliferative disease.Type: ApplicationFiled: April 20, 2012Publication date: August 16, 2012Applicants: ASTEX THERAPEUTICS LIMITED, NOVARTIS AGInventors: Christopher Thomas BRAIN, Moo Je SUNG, Gebhard THOMA
-
Patent number: 8241627Abstract: The present invention provides a method for stabilizing a protein in a desired conformation by introducing at least one disulfide bond into the polypeptide. Computational design is used to identify positions where crysteine residues can be introduced to form a disulfide bond in only one protein conformation, and therefore lock the protein in a given conformation. Accordingly, antibody and small molecule therapeutics are selected that are specific for the desired protein conformation. The invention also provides modified integrin I-domain polypeptides that are stabilized in a desired conformation. The invention further provides screening assays and therapeutic methods utilizing the modified integrin I-domains of the invention.Type: GrantFiled: June 22, 2011Date of Patent: August 14, 2012Assignee: The Center for Blood Research, Inc.Inventors: Timothy A. Springer, Motomu Shimaoka, Chafen Lu
-
Patent number: 8236308Abstract: The present invention relates to uses of bispecific antibodies exhibiting cross-species specificity for evaluating the in vivo safety and/or activity and/or pharmacokinetic profile of the same in non-human species and humans. The present invention moreover relates to methods for evaluating the in vivo safety and/or activity and/or pharmacokinetic profile of said bispecific anti-bodies exhibiting cross-species specificity. The present invention also relates to methods of measuring the biological activity and/or efficacy of such bispecific antibodies exhibiting cross-species specificity. In addition, the present invention relates to pharmaceutical compositions comprising bispecific single chain antibodies exhibiting cross-species specificity and to methods for the preparation of pharmaceutical compositions comprising said bispecific single chain antibodies exhibiting cross-species specificity for the treatment of diseases.Type: GrantFiled: October 10, 2006Date of Patent: August 7, 2012Assignee: Micromet AGInventors: Roman Kischel, Tobias Raum, Bernd Schlereth, Doris Rau, Ronny Cierpka, Peter Kufer
-
Patent number: 8236314Abstract: This invention provides an agonist antibody to a human thrombopoietin receptor (human c-Mpl), and pharmaceutical compositions comprising the same for use in treatment of thrombocytopenia. The disclosed agonist antibody comprises (1) antibody constant regions comprising heavy and light chain constant regions, each of which may optionally contain domain substitutions, or may contain deletions, substitutions, additions, or insertions of amino acid residues, and (2) antibody variable regions capable of binding to and activating a human thrombopoietin receptor. The-agonist antibody further induces colony formation at a concentration of 10,000 ng/ml or lower, and has a maximal activity at least 50% higher than that of PEG-rHuMGDF and an 50% effective concentration (EC50) of 100 nM or less.Type: GrantFiled: September 14, 2011Date of Patent: August 7, 2012Assignee: Kyowa Hakko Kirin Co., Ltd.Inventors: Masayuki Kai, Kazuhiro Motoki, Shiro Kataoka, Hideaki Yoshida, Tetsuya Hagiwara
-
Patent number: 8236313Abstract: Provided herein are compositions and methods for preventing, ameliorating, and/or reducing tissue ischemia and/or tissue damage due to ischemia, increasing blood vessel diameter, blood flow and tissue perfusion in the presence of vascular disease including peripheral vascular disease, atherosclerotic vascular disease, coronary artery disease, stroke and influencing other conditions, by suppressing CD47 and/or blocking TSP1 and/or CD47 activity or interaction. Influencing the interaction of CD47-TSP1 in blood vessels allows for control of blood vessel diameter and blood flow, and permits modification of blood pressure and cardiac function. Under conditions of decreased blood flow, for instance through injury or atherosclerosis, blocking TSP1-CD47 interaction allows blood vessels to dilate and increases blood flow, tissue perfusion and tissue survival. This in turn reduces or prevents tissue necrosis and death.Type: GrantFiled: October 5, 2007Date of Patent: August 7, 2012Assignees: The United States of America, as represented by the Secretary of the Department of Health and Human Services, Washington UniversityInventors: Jeffrey S. Isenberg, David D. Roberts, William A. Frazier
-
Publication number: 20120189621Abstract: This invention relates generally to compositions that contain multiple modulating agents, e.g., multiple modulating agents that target CD3 on T cells and neutralize one or more biological activities of interleukin-6 (IL-6), such as CD3 modulators including anti-CD3 antibodies and anti-IL-6 antagonists including anti-IL-6 antibodies, anti-IL-6R antagonists including anti-IL-6R antibodies, and/or anti-IL-6/IL-6R complex antagonists including anti-IL-6/IL-6R binding antibodies, and methods of using these compositions in the treatment, amelioration and/or prevention of relapse of an autoimmune disease.Type: ApplicationFiled: January 20, 2012Publication date: July 26, 2012Inventors: Yann Dean, Fabien Depis
-
Patent number: 8226950Abstract: The present invention disclosed recombinant anti-VLA-4 antibody molecules, including humanized recombinant anti-VLA-4 antibody molecules. These antibodies are useful in the treatment of specific and non-specific inflammation, including asthma and inflammatory bowel disease. In addition, the humanized recombinant anti-VLA-4 antibodies disclosed can be useful in methods of diagnosing and localizing sites of inflammation.Type: GrantFiled: September 27, 2010Date of Patent: July 24, 2012Assignee: Biogen Idec MA Inc.Inventors: Roy R. Lobb, Frank J. Carr, Philip R. Tempest
-
Patent number: 8221756Abstract: The invention relates to C2a inhibitors, which bind to C2a and block the functional activity of C2a in complement activation. The inhibitors include antibody molecules, as well as homologues, analogues and modified or derived forms thereof, including immunoglobulin fragments like Fab, F(ab?)2 and Fv, small molecules, including peptides, oligonucleotides, peptidomimetics and organic compounds. A monoclonal antibody, which bound to C2a and blocked its ability to activate complement was generated and designated 175-62. The hybridoma producing this antibody was deposited at the American Type Culture Collection, 10801 University Blvd., Manassas, Va. 20110-2209, under Accession Number PTA-1553.Type: GrantFiled: March 11, 2011Date of Patent: July 17, 2012Assignee: Genentech, Inc.Inventors: Michael S. C. Fung, Cecily R. Y. Sun, William N. C. Sun
-
Patent number: 8221755Abstract: The present invention relates generally to antibodies that bind to the Interleukin-13 receptor.alpha.1 chain (IL-13R.alpha.1) and antagonize IL-13 receptor-mediated signaling by IL-13 and/or IL-4. More particularly, the present invention provides humanized or human antibodies to mammalian and in particular IL-13R.alpha.1. These antibodies have uses in the treatment or prevention of IL-13- and/or IL-4-mediated diseases or conditions. The present invention further contemplates a method of modulating IL-13- and/or IL-4-mediated diseases or conditions by the administration of the subject antibodies. The present invention further provides an assay system useful for identifying antibodies or other agents which modulate IL-13 and/or IL-4 signaling through an IL-13 receptor complex. Accordingly, a method of screening for modulators of IL-13R.alpha.1/ligand interaction is also provided.Type: GrantFiled: July 1, 2010Date of Patent: July 17, 2012Assignee: Zenyth Operations Pty Ltd.Inventors: Felicity Meredith Dunlop, Manuel Baca, Andrew Donald Nash, Louis Jerry Fabri, Douglas James Hilton, Nicos A. Nicola
-
Patent number: 8221757Abstract: The present invention relates to antibodies which bind to C5aR and which are useful in diagnostic and therapeutic methods. The antibodies of the present invention are reactive with an extracellular loop of C5aR other than the N-terminal domain and are capable of substantially reducing or inhibiting the binding of C5a to C5aR and functional consequences of neutrophil chemoattractant receptor activation.Type: GrantFiled: October 24, 2011Date of Patent: July 17, 2012Assignee: G2 Therapies LtdInventor: Charles Reay MacKay
-
Patent number: 8216579Abstract: The present invention relates to humanized Fc?RIIB antibodies, fragments, and variants thereof that bind human Fc?RIIB with a greater affinity than said antibody binds Fc?RIIA. The invention encompasses the use of the humanized antibodies of the invention for the treatment of any disease related to loss of balance of Fc receptor mediated signaling, such as cancer, autoimmune and inflammatory disease. The invention provides methods of enhancing the therapeutic effect of therapeutic antibodies by administering the humanized antibodies of the invention to enhance the effector function of the therapeutic antibodies. The invention also provides methods of enhancing the efficacy of a vaccine composition by administering the humanized antibodies of the invention. The invention encompasses methods for treating an autoimmune disease and methods for elimination of cancer cells that express Fc?RIIB.Type: GrantFiled: May 21, 2010Date of Patent: July 10, 2012Assignee: MacroGenics, Inc.Inventors: Leslie S. Johnson, Ling Huang
-
Patent number: 8206711Abstract: Chronic Lymphocytic Leukemia (CLL) may be treated with antibodies directed against the CD20 antigen.Type: GrantFiled: December 2, 2009Date of Patent: June 26, 2012Assignees: Biogen Idec Inc., Genentech, Inc.Inventors: Christine A. White, Antonio J. Grillo-Lopez, John G. Curd, Susan Desmond-Hellmann
-
Publication number: 20120148676Abstract: The present invention contemplates induction of immunological tolerance thereby providing permanent allogcaft acceptance. This method obviates the need for a lifelong regimen of immunosuppressive agents which can increase the risk of infection, autoimmunity, and cancer. Immunological tolerance is thought to be mediated by regulatory T lymphocytes (Treg cells) with immunosuppressive capabilities. A therapeutically relevant platform comprising artificial constructs are contemplated comprising numerous soluble and surface bound Treg cell stimulating factors that may induce tolerance following allograft transplantation. Such artificial constructs, being the size of a cell, have surface bound monoclonal antibodies specific to regulatory T-cell surface moieties and encapsulated soluble regulatory T-cell modulating factors.Type: ApplicationFiled: July 9, 2010Publication date: June 14, 2012Inventor: Steven R. Little
-
Patent number: 8197814Abstract: A recombinant antibody or the antibody fragment thereof which specifically reacts with an extracellular domain of human CCR4; a DNA which encodes the recombinant antibody or the antibody fragment thereof; a method for producing the recombinant antibody or the antibody fragment thereof; a method for immunologically detecting CCR4, a method for immunologically detecting a cell which expressed CCR4 on the cell surface, a method for depleting a cell which expresses CCR4 on the cell surface, and a method for inhibiting production of Th2 cytokine, which comprise using the recombinant antibody according or antibody fragment thereof; a therapeutic or diagnostic agent for Th2-mediated immune diseases; and a therapeutic or diagnostic agent for a blood cancer.Type: GrantFiled: January 8, 2010Date of Patent: June 12, 2012Assignee: Kyowa Hakko Kirin Co., Ltd.Inventors: Kenya Shitara, Nobuo Hanai, Emi Shoji, Mikiko Sakurada, Akiko Furuya, Kazuyasu Nakamura, Rinpei Niwa, Kenji Shibata, Motoo Yamasaki
-
Patent number: 8192741Abstract: The present invention provides methods of preventing or treating rheumatoid arthritis using a fully human antibody or antigen-binding fragment thereof that specifically binds human interleukin-6 receptor (hIL-6R). The methods of the present invention may include administration of a second therapeutic agent, such as one or more of a non-steroidal anti-inflammatory drug (NSAID), a glucocorticoid, a disease-modifying anti-rheumatic drug (DMARD), or a TNF-alpha antagonist, T-cell blocker, anti-CD20 antibody, an IL-1, JAK or IL-17 antagonist, or any combination thereof.Type: GrantFiled: November 1, 2011Date of Patent: June 5, 2012Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Allen Radin, Sean Stevens, Tammy T. Huang, Joel H. Martin, Jeanette L. Fairhurst, Ashique Rafique, Eric Smith, Kevin J. Pobursky, Nicholas J. Papadopoulos, James P. Fandl, Gang Chen, Margaret Karow
-
Patent number: 8182812Abstract: Isolated human monoclonal antibodies which bind to and inhibit human CD25, and related antibody-based compositions and molecules, are disclosed. The human antibodies can be produced by a hybridoma, a transfectoma or in a nonhuman transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are pharmaceutical compositions comprising the human antibodies, nonhuman transgenic animals, hybridomas and transfectomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.Type: GrantFiled: September 16, 2008Date of Patent: May 22, 2012Assignee: Genmab A/SInventors: Janine Schuurman, Catharina Emanuele Gerarda Havenith, Paul Parren, Jan G. J. Van De Winkel, Denise Leah Williams, Jorgen Petersen, Ole Baadsgaard
-
Patent number: 8182816Abstract: Disclosed are methods of treating subjects having cancers including administering an effective amount of an early activation molecule agonist, antagonist or depletor, to the subject. Human monoclonal antibodies specific to the early activation molecules, and methods of use, are also disclosed.Type: GrantFiled: November 11, 2010Date of Patent: May 22, 2012Assignees: Universidad Autonoma de Madrid, Consejo Superior de Investigaciones CientificasInventors: Francisco Sanchez-Madrid, Carlos-Martinez Alonso, David Sancho Madrid, Pablo Engel Rocamora, Enric Esplugues Artola, Javier Vega Ramos, Pilar Lauzurica Gomez
-
Patent number: 8178098Abstract: Disclosed is a method to reduce airway hyperresponsivesness in an animal by the direct delivery to the lungs of aerosolized antibodies against T cell receptors. The method is particularly useful for treating airway hyperresponsiveness associated with allergic inflammation, is effective at extremely low doses of antibody, and does not have a substantial effect on the peripheral immune system.Type: GrantFiled: April 3, 2001Date of Patent: May 15, 2012Assignee: National Jewish HealthInventors: Michael F. Lahn, Willi K. Born, Arihiko Kanehiro, Erwin Gelfand
-
Publication number: 20120107233Abstract: This invention relates to the diagnosis and treatment of cancerous diseases, particularly to the mediation of cytotoxicity of tumor cells; and most particularly to the use of cancerous disease modifying antibodies (CDMAB), optionally in combination with one or more chemotherapeutic agents, as a means for initiating the cytotoxic response. The invention further relates to binding assays which utilize the CDMAB of the instant invention.Type: ApplicationFiled: August 15, 2011Publication date: May 3, 2012Applicant: HOFFMANN-LA ROCHE INC.Inventors: David S.F. Young, Helen P. Findlay, Susan E. Hahn, Lisa M. Cechetto, Fortunata McConkey
-
Patent number: 8168427Abstract: The present invention provides antibodies useful as therapeutics for treating and/or preventing diseases associated with cells expressing CLD18, including tumor-related diseases such as gastric cancer, esophageal cancer, pancreatic cancer, lung cancer, ovarian cancer, colon cancer, hepatic cancer, head-neck cancer, and cancer of the gallbladder.Type: GrantFiled: November 24, 2006Date of Patent: May 1, 2012Assignees: Ganymed Pharmaceuticals AG, Johannes Gutenberg-Universitat MainzInventors: Ugur Sahin, Ozlem Tureci, Dirk Usener, Stefan Fritz, Cristoph Uherek, Gunda Brandenburg, Harald-Gerhard Geppert, Anja Kristina Schroder, Philippe Thiel
-
Patent number: 8163291Abstract: The present invention concerns methods and compositions for stably tethered structures of defined compositions, which may have multiple functionalities and/or binding specificities. Particular embodiments concern homodimers comprising monomers that contain a dimerization and docking domain attached to a precursor. The precursors may be virtually any molecule or structure, such as antibodies, antibody fragments, antibody analogs or mimetics, aptamers, binding peptides, fragments of binding proteins, known ligands for proteins or other molecules, enzymes, detectable labels or tags, therapeutic agents, toxins, pharmaceuticals, cytokines, interleukins, interferons, radioisotopes, proteins, peptides, peptide mimetics, polynucleotides, RNAi, oligosaccharides, natural or synthetic polymeric substances, nanoparticles, quantum dots, organic or inorganic compounds, etc. Other embodiments concern tetramers comprising a first and second homodimer, which may be identical or different.Type: GrantFiled: May 19, 2009Date of Patent: April 24, 2012Assignee: IBC Pharmaceuticals, Inc.Inventors: Chien-Hsing Chang, David M. Goldenberg, William J. McBride, Edmund A. Rossi
-
Patent number: 8153125Abstract: The present invention relates to CD20 binding molecules and nucleic acid sequences encoding CD20 binding molecules. In particular, the present invention relates to CD20 binding molecules with a high binding affinity, and a low dissociation rate, with regard to human CD20. Preferably, the CD20 binding molecules of the present invention comprise light and/or heavy chain variable regions with fully human frameworks (e.g. human germline frameworks).Type: GrantFiled: May 20, 2004Date of Patent: April 10, 2012Assignee: Applied Molecular Evolution, Inc.Inventors: Jeffry D. Watkins, Julian Davies, David M. Marquis, Barrett W Allan, Brian Ondek
-
Patent number: 8153130Abstract: A test method that provides data useful in predicting the probability of onset of acute graft-versus-host disease (GVHD) is described along with a kit for performing the method, and a pharmaceutical preparation and a molecular targeted therapy for treating or preventing GVHD. The test method includes measuring the blood DNAM-1 concentration of a patient of hematopoietic stem cell transplantation from bone marrow or the like over a period after the transplantation to provide data concerning the transition of the concentration to an abnormally high level deviating from the normal range, whereby the probability of the development of acute graft-versus-host disease is predicted, the risk of the development is estimated, or therapeutic effects after the development are evaluated.Type: GrantFiled: April 5, 2007Date of Patent: April 10, 2012Assignee: University of TsukubaInventors: Akira Shibuya, Hiroshi Kojima
-
Patent number: 8147831Abstract: The present invention provides humanized, chimeric and human anti-CD19 antibodies, anti-CD19 antibody fusion proteins, and fragments thereof that bind to a human B cell marker. Such antibodies, fusion proteins and fragments thereof are useful for the treatment and diagnosis of various B-cell disorders, including B-cell malignancies and autoimmune diseases. In more particular embodiments, the humanized anti-CD19 antibodies may comprise one or more framework region amino acid substitutions designed to improve protein stability, antibody binding and/or expression levels. In a particularly preferred embodiment, the substitutions comprise a Ser91Phe substitution in the hA19 VH sequence.Type: GrantFiled: October 19, 2010Date of Patent: April 3, 2012Assignee: Immunomedics, Inc.Inventors: Hans J. Hansen, Zhengxing Qu, David M. Goldenberg
-
Patent number: 8147832Abstract: A CD20-binding polypeptide composition comprising a combination of a modified heavy chain variable region polypeptide and a modified light chain variable region polypeptide. The combination can be (a) a modified 2B8 antibody heavy chain variable region polypeptide of SEQ ID NO: 48; and a modified 2B8 antibody light chain variable region polypeptide of SEQ ID NO: 49; or (b) a modified Leu16 antibody heavy chain variable region polypeptide of SEQ ID NO: 50; and a modified Leu16 antibody light chain variable region polypeptide of SEQ ID NO: 51.Type: GrantFiled: August 13, 2004Date of Patent: April 3, 2012Assignee: Merck Patent GmbHInventors: Francis Joseph Carr, Stephen Williams, Stephen D. Gillies
-
Publication number: 20120076753Abstract: The invention relates to use of the natural cytotoxicity receptor NKp46 for preventing and treating diabetes, including type I diabetes (TID) and type 2 diabetes. In particular, the invention provides compositions comprising a fragment of the extracellular region of NKp46 for preventing the onset and progression of diabetes.Type: ApplicationFiled: March 18, 2010Publication date: March 29, 2012Inventors: Ofer Mandelboim, Angel Porgador, Yaakov Naparstek, Chamutal Gur
-
Patent number: 8142783Abstract: Novel fully human anti-VAP-1 antibodies and fragments thereof are disclosed. Nucleic acids encoding anti-VAP-1 antibodies or fragments thereof, as well as expression vectors and host cells incorporating these nucleic acids for the recombinant expression of anti-VAP-1 antibodies are also given. Pharmaceutical compositions comprising said antibodies and therapeutic uses thereof are also disclosed.Type: GrantFiled: November 5, 2010Date of Patent: March 27, 2012Assignee: Biotie Therapies Corp.Inventors: David John Smith, Petri Vainio, Jari Mikkola, Päivi Vuorio, Jani Vainio
-
Patent number: 8137670Abstract: The present invention relates to the discovery of antibodies that bind to novel epitopes present on membrane-anchored IgE and which bind to these novel epitopes on the surface of B cells and plasma cells. In addition, the antibodies of the present invention can mediate ADCC and can be useful to deplete those B cells and plasma cells expressing the novel epitopes of the invention. The antibodies of the present invention can be useful for the treatment of IgE-mediated diseases. Accordingly the present invention also provides compositions and methods for the prevention, management, treatment or amelioration of IgE-mediated diseases.Type: GrantFiled: September 28, 2006Date of Patent: March 20, 2012Assignee: MedImmune, LLCInventors: Herren Wu, Peter Kiener, Partha S. Chowdhury, James F. Young
-
Patent number: 8137672Abstract: A synergistic adjuvant is provided comprising synergistically effective amounts of at least one type 1 interferon and at least one CD40 agonist, wherein these moieties may be in the same or separate compositions. In addition, fusion proteins and DNA conjugates which contain a type 1 interferon/CD40 agonist/antigen combination are provided. The use of these compositions, protein and DNA conjugates as immune adjuvants for treatment of various chronic diseases such as HIV infection and for enhancing the efficacy of vaccines (prophylactic and therapeutic) is also provided.Type: GrantFiled: June 21, 2011Date of Patent: March 20, 2012Assignee: The Regents of the University of ColoradoInventors: Ross Kedl, Phillip J. Sanchez, Catherine Haluszczak
-
Patent number: 8133490Abstract: A method to treat cancer uses ultrapheresis, refined to remove compounds of less than 120,000 daltons molecular weight, followed by administration of replacement fluid, to stimulate the patient's immune system to attack solid tumors. In the preferred embodiment, the patient is ultrapheresed using a capillary tube ultrafilter having a pore size of 0.02 to 0.05 microns, with a molecular weight cutoff of 120,000 daltons, sufficient to filter one blood volume. The preferred replacement fluid is ultrapheresed normal plasma. The patient is preferably treated daily for three weeks, diagnostic tests conducted to verify that there has been shrinkage of the tumors, then the treatment regime is repeated. The treatment is preferably combined with an alternative therapy, for example, treatment with an anti-angiogenic compound, one or more cytokines such as TNF, gamma interferon, or IL-2, or a procoagulant compound. The treatment increases endogenous, local levels of cytokines, such as TNF.Type: GrantFiled: October 30, 2007Date of Patent: March 13, 2012Assignee: Biopheresis Technologies, Inc.Inventor: M. Rigdon Lentz
-
Patent number: 8119135Abstract: The present invention provides anti-thrombotic agents, methods for screening for said anti-thrombotics agents and methods of treating thrombotic and other cardiovascular disorders.Type: GrantFiled: January 16, 2009Date of Patent: February 21, 2012Assignees: Helmhotz Zentrum Munchen, Deutsches Forschungszentrum fur Gesundheit und Umwelt (GmbH), Corimmun GmbHInventors: Götz Münch, Meinrad Gawaz, Andreas Bültmann, Elisabeth Kremmer
-
Publication number: 20120039902Abstract: The present invention relates generally to binding agents useful in the selective depletion of T cells in vivo. More specifically, the invention relates to ICOS-binding agents which once bound to ICOS expressed on the surface of cells, in particular ICOS-bearing activated T cells, result in the in vivo depletion of cells to which they are bound. Methods of treating T cell related diseases using said ICOS-binding agents, and pharmaceutical compositions comprising said ICOS-binding agents, a method of identifying an ICOS-binding agent, and monoclonal anti-ICOS antibodies capable of eliminating cells in vivo which express ICOS on their surface are also provided.Type: ApplicationFiled: April 22, 2005Publication date: February 16, 2012Inventor: Richard Kroczek
-
Publication number: 20120039903Abstract: Disclosed herein are methods for suppressing an immune response in a subject, treating a neoplasm in a subject, or treating a fibroproliferative vascular disease in a subject, that includes administering to the subject a therapeutically effective amount of a 2-(4-piperazinyl)-substituted 4H-1-benzopyran-4-one compound, or a pharmaceutically acceptable salt thereof, having the structure of wherein the presence of each of R1 and R2 is optional and R1 and R2 are each independently selected from alkyl, substituted alkyl, heteroalkyl, cycloalkyl, substituted cycloalkyl, heterocycloalkyl, substituted heterocycloalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, alkoxy, halogen, hydroxy, or amino.Type: ApplicationFiled: September 22, 2011Publication date: February 16, 2012Inventors: Joel Moss, Arnold Kristof
-
Patent number: 8110193Abstract: Allogeneic hematopoietic cell transplantation (HCT) is an effective therapy for treatment of hematological malignancies and various autoimmune conditions. However, HCT traditionally requires conditioning by total body irradiation and/or chemotherapy, both of which are toxic and induce GVHD. Provided herein are compositions and methods for conditioning a subject for HCT by administering one or more anti-CD3 compounds and one or more histone deacetylase inhibitors. Also provided herein are methods for reducing GVHD in a subject receiving total body irradiation prior to HCT comprising administering one or more anti-CD3 compounds to the subject prior to total body irradiation.Type: GrantFiled: December 18, 2008Date of Patent: February 7, 2012Assignee: City of HopeInventor: Defu Zeng
-
Patent number: 8105595Abstract: This invention provides monoclonal antibodies that recognize the Toll-like Receptor 4/MD-2 receptor complex, and monoclonal antibodies that recognize the TLR4/MD2 complex as well as TLR4 when not complexed with MD-2. The invention further provides methods of using the humanized monoclonal antibodies as therapeutics. This invention also provides soluble chimeric proteins, methods of expressing and purifying soluble chimeric proteins, and methods of using soluble chimeric proteins as therapeutics, in screening assays and in the production of antibodies.Type: GrantFiled: March 8, 2010Date of Patent: January 31, 2012Assignee: NovImmune S.A.Inventors: Greg Elson, Olivier Leger
-
Patent number: 8105596Abstract: B-cell malignancies, such as the B-cell subtype of non-Hodgkin's lymphoma and chronic lymphocytic leukemia, are significant contributors to cancer mortality. The response of B-cell malignancies to various forms of treatment is mixed. Traditional methods of treating B-cell malignancies, including chemotherapy and radiotherapy, have limited utility due to toxic side effects. Immunotherapy with anti-CD20 antibodies have also provided limited success. The use of antibodies that bind with the CD22 or CD19 antigen, however, provides an effective means to treat B-cell malignancies such as indolent and aggressive forms of B-cell lymphomas, and acute and chronic forms of lymphatic leukemias. Moreover, immunotherapy with anti-CD22 and/or anti-CD19 antibodies requires comparatively low doses of antibody protein, and can be used effectively in multimodal therapies.Type: GrantFiled: March 15, 2011Date of Patent: January 31, 2012Assignee: Immunomedics, Inc.Inventor: David M. Goldenberg
-
Publication number: 20120020981Abstract: This invention provides fully human monoclonal antibodies that recognize the IL-6/IL-6R complex. The invention further provides methods of using such monoclonal antibodies as a therapeutic, diagnostic, and prophylactic.Type: ApplicationFiled: September 7, 2011Publication date: January 26, 2012Inventors: Walter Ferlin, Marie Kosco-Vilbois, Greg Elson, Olivier Leger, Florence Guilhot
-
Patent number: 8101179Abstract: A murine anti-CD20 monoclonal antibody having cell growth inhibitory activities is disclosed. Cell growth inhibitory activities include apoptosis against human CD20 antigen expressing cells in culture of the CD20 antigen expressing cells without effector cells. The anti-CD20 monoclonal antibody is incorporated into chimeric anti-CD20 monoclonal antibodies in which the amino acid sequences of the variable regions of the anti-CD20 monoclonal antibody and the amino acid sequences of the constant regions of human immunoglobulin are fused. Also a humanized anti-CD20 monoclonal antibody is described which includes all of the variable region CDRs of the H chain of the anti-CD20 monoclonal antibody and all of the variable region CDRs of the L chain of the anti-CD20 monoclonal antibody and an amino acid sequence of human immunoglobulin. A nucleotide sequence encoding the amino acid sequence of the chimeric or humanized anti-CD20 monoclonal antibody can be expressed in mammalian cells.Type: GrantFiled: March 31, 2006Date of Patent: January 24, 2012Assignee: Biomedics Inc.Inventors: Masanori Numazaki, Tetsuo Nakamura, Sadakazu Usuda, Eduardo A. Padlan
-
Publication number: 20120003183Abstract: The present disclosure is directed to novel crystalline addition salts of (i) tromethamine with (ii) an azabiphenylaminobenzoic acid derivatives of formula (I), pharmaceutically acceptable solvates thereof, pharmaceutical combinations thereof, and methods of treatment.Type: ApplicationFiled: March 11, 2010Publication date: January 5, 2012Inventors: Nuria Garcia Gonzalez, Francesc Carrera Carrera, Monserrat Julia Jane, Laurent Debethune, Xavier Serra Masia
-
Patent number: 8088378Abstract: The present invention is directed to anti-CD79b antibody, huMA79b.v28, and compositions of matter thereof useful for the treatment of hematopoietic tumor in mammals and to methods of using those compositions of matter for the same.Type: GrantFiled: July 15, 2008Date of Patent: January 3, 2012Assignee: Genetech Inc.Inventors: Yvonne Chen, Mark Dennis, David Dornan, Kristi Elkins, Jagath Reddy Junutula, Andrew Polson, Bing Zheng
-
Patent number: 8088383Abstract: Methods of therapy for B-cell malignancies are provided. The methods comprise administering a therapeutically effective amount of an antagonist anti-CD40 antibody or antigen-binding fragment thereof to a patient in need thereof. The antagonist anti-CD40 antibody or antigen-binding fragment thereof is free of significant agonist activity when the antibody binds a CD40 antigen on a normal human B cell, exhibits antagonist activity when the antibody binds a CD40 antigen on a malignant human B cell, and can exhibit antagonist activity when the antibody binds a CD40 antigen on a normal human B cell. Antagonist activity of the anti-CD40 antibody or antigen-binding fragment thereof beneficially inhibits proliferation and/or differentiation of malignant human B cells.Type: GrantFiled: September 27, 2010Date of Patent: January 3, 2012Assignee: Novartis Vaccines and Diagnostics, Inc.Inventors: Keting Chu, Lorianne K. Masuoka
-
Patent number: 8084031Abstract: A method for the treatment of inflammatory disorders is disclosed, particularly the treatment of arthritis. The method comprises the administration of a function blocking antibody which is capable of binding an epitope of VLA-1.Type: GrantFiled: November 11, 2008Date of Patent: December 27, 2011Assignee: Biogen Idec MA Inc.Inventors: Philip Gotwals, Antonin De Fougerolles, Roy Lobb, Victor Kotelianski
-
Patent number: 8080248Abstract: The present invention provides methods of preventing or treating rheumatoid arthritis using a fully human antibody or antigen-binding fragment thereof that specifically binds human interleukin-6 receptor (hIL-6R). The methods of the present invention may include administration of a second therapeutic agent, such as one or more of a non-steroidal anti-inflammatory drug (NSAID), a glucocorticoid, a disease-modifying anti-rheumatic drug (DMARD), or a TNF-alpha antagonist, T-cell blocker, anti-CD20 antibody, an IL-1, JAK or IL-17 antagonist, or any combination thereof.Type: GrantFiled: May 14, 2010Date of Patent: December 20, 2011Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Allen Radin, Sean Stevens, Tammy T. Huang, Joel H. Martin, Jeanette L. Fairhurst, Ashique Rafique, Eric Smith, Kevin J. Pobursky, Nicholas J. Papadopoulos, James P. Fandl, Gang Chen, Margaret Karow
-
Patent number: 8080639Abstract: A new receptor family has been identified, of activin-like kinases. Novel proteins have activin/TGF-?-type I receptor functionality, and have consequential diagnostic/therapeutic utility. They may have a serine/threonine kinase domain, a DFKSRN or DLKSKN sequence in subdomain VIB and/or a GTKRYM sequence in subdomain VIII.Type: GrantFiled: October 31, 2007Date of Patent: December 20, 2011Assignee: Ludwig Institute for Cancer ResearchInventors: Kohei Miyazono, Peter ten Dijke, Petra Franzen, Hidetoshi Yamashita, Carl-Henrik Heldin
-
Patent number: 8080554Abstract: A method is provided herein to increase an immune response to an antigen. The method includes administering an agent that inhibits extracellular adenosine or inhibits adenosine receptors. Also disclosed are methods to increase the efficacy of a vaccine and to increase an immune response to a tumor antigen or immune cell-mediated tumor destruction.Type: GrantFiled: November 14, 2002Date of Patent: December 20, 2011Assignee: The United States of America as represented by the Secretary of the Department of Health and Human ServicesInventors: Michail V. Sitkovsky, Akio Ohta
-
Publication number: 20110300142Abstract: The invention relates to the use of 1-(?-D-Ribofuranosyl)-1,2-dihydropyrimidin-2-one derivative or mimetic or an analogue, derivatives, metabolites, variants or salts thereof for the manufacturing of a medicament to increase the amount of Indoleamine 2,3-dioxygenase (IDO) production in order to induce immunological tolerance as well as a method of treating a mammal in need thereof.Type: ApplicationFiled: May 26, 2008Publication date: December 8, 2011Inventors: Leif G. Salford, Bertil Persson, Hans Olov Sjögren, Bengt Widegren
-
Patent number: 8071096Abstract: The present invention relates to antibodies which bind to C5aR and which are useful in diagnostic and therapeutic methods. The antibodies of the present invention are reactive with an extracellular loop of C5aR other than the N-terminal domain and are capable of substantially reducing or inhibiting the binding of C5a to C5aR and functional consequences of neutrophil chemoattractant receptor activation.Type: GrantFiled: January 24, 2003Date of Patent: December 6, 2011Assignee: G2 Therapies LtdInventor: Charles Reay MacKay
-
Patent number: 8071097Abstract: The present application relates to apoptotic anti-IgE antibodies, nucleic acid encoding the same, therapeutic compositions thereof, and their use in the treatment of IgE-mediated disorders.Type: GrantFiled: March 21, 2008Date of Patent: December 6, 2011Assignee: Genentech, Inc.Inventors: Lawren Wu, Mercedesz Balazs, Hans Brightbill, Andrew Chan, Yvonne Chen, Anan Chuntharapai, Mark Dennis, Terence Wong
-
Patent number: 8063187Abstract: The present invention relates to immunoglobulins that bind Fc?RIIb+ cells and coengage the antigen on the cell's surface and an Fc?RIIb on the cell's surface, methods for their generation, and methods for using the immunoglobulins.Type: GrantFiled: May 30, 2008Date of Patent: November 22, 2011Assignee: Xencor, Inc.Inventors: Seung Yup Chu, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar, Gregory L. Moore, Igor Vostiar